Evidence map›Paper›PMID 39825756›Full record

ArticleJournal of paediatrics and child health2025

Study of Children Aged Under 2 Years Admitted With RSV at Four Australian Hospitals [2021-2022].

Nigel W Crawford, Annette Alafaci, Julia E Clark, Joshua R Francis, Christopher C Blyth, Catherine Pienaar, Cara Minney-Smith, Sonia Dougherty, Anjalee Panditha, Laura Francis and 1 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of paediatrics and child health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Respiratory syncytial virus epidemiology and effectiveness of infant nirsevimab: 2024 results from the Australian Sentinel Hospital Network (FluCAN-PAEDS).Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Nigel W CrawfordThe Royal Children's Hospital, Parkville, Victoria, Australia.
Annette AlafaciSurveillance of Adverse Events Following Vaccination in the Community (SAEFVIC), Murdoch Children's Research Institute, Parkville, Victoria, Australia.
Julia E ClarkInfection Management Service, Childrens Health Queensland, Brisbane, Queensland, Australia.
Joshua R FrancisGlobal and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia.ORCID https://orcid.org/0000-0001-9302-4543
Christopher C BlythWesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Nedlands, Western Australia, Australia.
Catherine PienaarWesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Nedlands, Western Australia, Australia.
Cara Minney-SmithDepartment of Microbiology, PathWest Laboratory Medicine WA, QEII Medical Centre, Nedlands, Western Australia, Australia.
Sonia DoughertyInfection Management Service, Childrens Health Queensland, Brisbane, Queensland, Australia.
Anjalee PandithaInfection Management Service, Childrens Health Queensland, Brisbane, Queensland, Australia.
Laura FrancisDepartment of Paediatrics, Royal Darwin Hospital, Darwin, Northern Territory, Australia.
Ian G BarrWHO Collaborating Centre for Reference and Research on Influenza, VIDRL, Doherty Institute, Melbourne, Victoria, Australia.

Funding

Department of Health and Aged Care, Australian GovernmentNHMRC, Australian Department of Health and Aged Care APP1173163WHO
6 · The paper itself

Abstract

aimsPrimary aim was to review severe acute respiratory infections (SARI) hospitalisations caused by respiratory syncytial virus (RSV) in children aged < 2 years in paediatric hospitals in Australia. Secondary aims included RSV subtyping, assessing RSV seasonality and contributing to the World Health Organisation's RSV surveillance programme.

methodsWe prospectively reviewed the medical records of children (< 2 years of age) with a confirmed SARI who were admitted to one of four major Australian paediatric hospitals and had a respiratory sample analysed by Polymerase Chain Reaction (PCR). A detailed dataset was completed for RSV positive cases.

resultsBetween 1 January 2021 and 31 December 2022, 2290 RSV (laboratory-confirmed) admissions were identified (53.4% of all SARI admissions). Approximately 50% of all RSV cases were aged 0-6 months. RSV-A predominated in 2021 with peak infections observed in summer while in 2022 RSV-B predominated with peak infections in the more traditional winter months. The median total length of stay (LOS) for RSV positive admissions was 46 h (IQR: 22-82 h). 9% of these children required an ICU admission with a prolonged median LOS 68 h (IQR: 40-112 h). Respiratory support utilisation was consistent over the 2 years. 1.8% required mechanical ventilation; 4.6% continuous positive airway pressure; 23.3% high flow oxygen; and 50.8% low flow oxygen.

conclusionsRSV in children continues to cause a significant disease burden at Australian tertiary paediatric centres. Ongoing hospital surveillance is required to document the impact of RSV preventative therapies that have become available in 2024.

Indexed as

HospitalizationRespiratory Syncytial Virus InfectionsRespiratory Tract InfectionsAustraliaFemaleHospitals, PediatricHumansInfantInfant, NewbornLength of StayMaleProspective StudiesRespiratory Syncytial Virus, HumanSeasonsdisease burdenrespiratory syncytial virus (RSV)severe acute respiratory infection (SARI)

Identifiers

PMID39825756
PMCPMC11883050

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.